Keywords
Last Name

Irene M. Gavras, MD

TitleEmeritus Professor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionHypertension
Address700 Albany St Ctr for Adv Biomed Res
Boston MA 02118
Phone(617) 638-4025
ORCID ORCID Icon0000-0001-9675-9983
 Research Expertise & Professional Interests
My clinical expertise is in evaluating complicated cases of hypertension and teaching medical students and house staff.
My research expertise is in the evaluation of experimental animal data and evaluation of clinical research results, as well as helping young trainees to prepare presentations.

 Self-Described Keywords
  • clinical research
  • hypertension
  • patient evaluation and treatment
 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Marketou ME, Kontaraki J, Zacharis E, Parthenakis F, Maragkoudakis S, Gavras I, Gavras H, Vardas PE. Differential gene expression of bradykinin receptors 1 and 2 in peripheral monocytes from patients with essential hypertension. J Hum Hypertens. 2014 Jul; 28(7):450-5. PMID: 24401952.
    View in: PubMed
  2. Manolis AJ, Poulimenos LE, Kallistratos MS, Gavras I, Gavras H. Sympathetic overactivity in hypertension and cardiovascular disease. Curr Vasc Pharmacol. 2014 Jan; 12(1):4-15. PMID: 23905597.
    View in: PubMed
  3. Marketou ME, Kintsurashvili E, Androulakis NE, Kontaraki J, Alexandrakis MG, Gavras I, Vardas PE, Gavras H. Blockade of platelet alpha2B-adrenergic receptors: a novel antiaggregant mechanism. Int J Cardiol. 2013 Oct 3; 168(3):2561-6. PMID: 23582690.
    View in: PubMed
  4. Gavras I, Gavras H. 'Volume-expanded' hypertension: the effect of fluid overload and the role of the sympathetic nervous system in salt-dependent hypertension. J Hypertens. 2012 Apr; 30(4):655-9. PMID: 22227820.
    View in: PubMed
  5. Manolis AJ, Marketou ME, Gavras I, Gavras H. Cardioprotective properties of bradykinin: role of the B(2) receptor. Hypertens Res. 2010 Aug; 33(8):772-7. PMID: 20505673.
    View in: PubMed
  6. Marketou M, Kintsurashvili E, Papanicolaou KN, Lucero HA, Gavras I, Gavras H. Cardioprotective effects of a selective B(2) receptor agonist of bradykinin post-acute myocardial infarct. Am J Hypertens. 2010 May; 23(5):562-8. PMID: 20186129.
    View in: PubMed
  7. Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens. 2009 Oct; 23(10):623-35. PMID: 19339998.
    View in: PubMed
  8. Kintsurashvili E, Shenouda S, Ona D, Ona L, Ahmad S, Ravid K, Gavras I, Gavras H. Hypertension in transgenic mice with brain-selective overexpression of the alpha(2B)-adrenoceptor. Am J Hypertens. 2009 Jan; 22(1):41-5. PMID: 18989257.
    View in: PubMed
  9. Silva VS, Martin LC, Franco RJ, Carvalho FC, Bregagnollo EA, Castro JH, Gavras I, Gavras H. Pleiotropic effects of statins may improve outcomes in atherosclerotic renovascular disease. Am J Hypertens. 2008 Oct; 21(10):1163-8. PMID: 18670414.
    View in: PubMed
  10. Duka A, Kintsurashvili E, Duka I, Ona D, Hopkins TA, Bader M, Gavras I, Gavras H. Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors. Hypertension. 2008 May; 51(5):1352-7. PMID: 18347228.
    View in: PubMed
  11. Gavras H, Gavras I . Vasopressin Inhibitors. In: Hypertension Primer, Fourth Edition. Editors: Joseph L. Izzo, Jr.,Domenic A. Sica and Henry R. Black. Lippincott Williams & Wilkins. Philadephia, PA. 2008; 474-476.
  12. Gavras I. The incidentally discovered adrenal mass. N Engl J Med. 2007 May 10; 356(19):2005-6. PMID: 17506163.
    View in: PubMed
  13. Sun B, Kintsurashvili E, Ona D, Ignjacev-Lazich I, Gavras I, Gavras H. Inhibition of the alpha(1D)-adrenergic receptor gene by RNA interference (RNAi) in rat vascular smooth muscle cells and its effects on other adrenergic receptors. Vascul Pharmacol. 2007 May; 46(5):367-72. PMID: 17307398.
    View in: PubMed
  14. Cardoso de Carvalho F, Bregagnollo E, Santos Silva V, Brunie A, da Silva Franco RJ, Martin LC, Gavras I, Gavras H. Frequency of coronary artery disease in patients with renal artery stenosis without clinical manifestations of coronary insufficiency. Am J Hypertens. 2006 Nov; 19(11):1125-8. PMID: 17070422.
    View in: PubMed
  15. Shenouda SM, Johns C, Kintsurashvili E, Gavras I, Gavras H. Long-term inhibition of the central alpha(2B)-adrenergic receptor gene via recombinant AAV-delivered antisense in hypertensive rats. Am J Hypertens. 2006 Nov; 19(11):1135-43. PMID: 17070424.
    View in: PubMed
  16. Martin LC, Franco RJ, Gavras I, Matsubara BB, Okoshi K, Zanati SG, Caramori JT, Barretti P, Balbi AL, Gavras H. Is 44-hour better than 24-hour ambulatory blood pressure monitoring in hemodialysis? Kidney Blood Press Res. 2006; 29(5):273-9. PMID: 17035712.
    View in: PubMed
  17. Triantafyllidi H, Kintsurashvili E, Johns C, Gavras I, Gavras H. Central plasmid antisense administration reduces blood pressure inhibiting alpha2B adrenoceptor gene expression in spontaneously hypertensive rats in vivo. Hellenic J Cardiol. 2006 May-Jun; 47(3):144-9. PMID: 16862820.
    View in: PubMed
  18. Rosenthal T, Gavras I. Fixed-drug combinations as first-line treatment for hypertension. Prog Cardiovasc Dis. 2006 May-Jun; 48(6):416-25. PMID: 16714161.
    View in: PubMed
  19. Duka A, Schwartz F, Duka I, Johns C, Melista E, Gavras I, Gavras H. A novel gene (Cmya3) induced in the heart by angiotensin II-dependent but not salt-dependent hypertension in mice. Am J Hypertens. 2006 Mar; 19(3):275-81. PMID: 16500513.
    View in: PubMed
  20. Duka A, Duka I, Gao G, Shenouda S, Gavras I, Gavras H. Role of bradykinin B1 and B2 receptors in normal blood pressure regulation. Am J Physiol Endocrinol Metab. 2006 Aug; 291(2):E268-74. PMID: 16507603.
    View in: PubMed
  21. Manolis A, Gavras I . Hypertension and the heart. In: The year in Hypertension. Editor: Hans Brunner. Clinical Publishing. Oxford, UK. 2006; 85-106.
  22. Ignjacev-Lazich I, Kintsurashvili E, Johns C, Vitseva O, Duka A, Shenouda S, Gavras I, Gavras H. Angiotensin-converting enzyme regulates bradykinin receptor gene expression. Am J Physiol Heart Circ Physiol. 2005 Nov; 289(5):H1814-20. PMID: 16219810.
    View in: PubMed
  23. Kintsurashvili E, Duka A, Ignjacev I, Pattakos G, Gavras I, Gavras H. Age-related changes of bradykinin B1 and B2 receptors in rat heart. Am J Physiol Heart Circ Physiol. 2005 Jul; 289(1):H202-5. PMID: 15708952.
    View in: PubMed
  24. Gavras I, Gavras H. The debate goes on--what is your choice? Am J Cardiol. 2005 Jan 1; 95(1):53-4. PMID: 15619394.
    View in: PubMed
  25. Manolis AJ, Iraklianou S, Pittaras A, Zaris M, Tsioufis K, Psaltiras G, Psomali D, Foussas S, Gavras I, Gavras H. Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy. Am J Hypertens. 2005 Jan; 18(1):18-22. PMID: 15691612.
    View in: PubMed
  26. Gavras I, Gavras H . ACE Inhibitor Trials: Effects in Hypertension. In: Hypertension: A companion to Brenner and Rectors the kidney, second edition. Editors: Suzanne Oparil, Michael A. Weber. Elsevier Saunders. Philadelphia, PA. 2005; 388-390.
  27. Martin LC, Franco RJ, Gavras I, Matsubara BB, Garcia S, Caramori JT, Barretti BB, Balbi AL, Barsanti R, Padovani C, Gavras H. Association between hypervolemia and ventricular hypertrophy in hemodialysis patients. Am J Hypertens. 2004 Dec; 17(12 Pt 1):1163-9. PMID: 15607624.
    View in: PubMed
  28. Gavras I, Rosenthal T. Combination therapy as first-line treatment for hypertension. Curr Hypertens Rep. 2004 Aug; 6(4):267-72. PMID: 15257860.
    View in: PubMed
  29. Gavras I, Gavras H. Hypertension, vasoactive peptides and coagulation factors. J Hypertens. 2004 Jun; 22(6):1091-2. PMID: 15167441.
    View in: PubMed
  30. Gavras I, Gavras H . Progress in stroke prevention: Lessons from the lastest trials. Cardiovasc Revs & Rpts. 2004; 25:229-231.
  31. Brunner H, Gavras I . Clinical trials of antihypertensive drugs. Gavras H, ed. In: The Year in Hypertension 2004. Clinical Publishing. Oxford, UK. 2004; 193-197.
  32. Voudris V, Avramides D, Gatzov P, Malakos J, Skoularigis J, Manolis A, Gavras H, Gavras I, Cokkinos DV. The effect of rapid decreases of blood pressure by different mechanisms on coronary flow and flow reserve in normal coronary arteries. Am J Hypertens. 2003 Dec; 16(12):1000-5. PMID: 14643572.
    View in: PubMed
  33. Duka I, Duka A, Kintsurashvili E, Johns C, Gavras I, Gavras H. Mechanisms mediating the vasoactive effects of the B1 receptors of bradykinin. Hypertension. 2003 Nov; 42(5):1021-5. PMID: 14557281.
    View in: PubMed
  34. Kintsurashvili E, Johns C, Ignjacev I, Gavras I, Gavras H. Central alpha2B-adrenergic receptor antisense in plasmid vector prolongs reversal of salt-dependent hypertension. J Hypertens. 2003 May; 21(5):961-7. PMID: 12714871.
    View in: PubMed
  35. Gavras I, Gavras H. Are patients who develop angioedema with ACE inhibition at risk of the same problem with AT1 receptor blockers? Arch Intern Med. 2003 Jan 27; 163(2):240-1. PMID: 12546617.
    View in: PubMed
  36. Gavras I. Prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med. 2002 May 23; 346(21):1667-9. PMID: 12030261.
    View in: PubMed
  37. Gavras I, Gavras H. Angiotensin II as a cardiovascular risk factor. J Hum Hypertens. 2002 May; 16 Suppl 2:S2-6. PMID: 11967726.
    View in: PubMed
  38. Gavras I, Gavras H. Metabolic effects of angiotensin-converting enzyme inhibition: the role of bradykinin. Current Opinion in Endocrinology & Diabetes. 2002; 9:323-328.
  39. Monteagudo PT, Gavras H, Gavras I, Kohlmann O, Ribeiro AB, Zanella MT. Role of vasopressin in 24-hour blood pressure regulation in diabetic patients with autonomic neuropathy. Am J Hypertens. 2002 Jan; 15(1 Pt 1):42-7. PMID: 11824859.
    View in: PubMed
  40. Gavras I, Gavras H. Angiotensin blockers in the treatment of hypertension. In: Harrison's Advances in Cardiology. Eugene Braunwald, ed. McGraw-Hill. 2002; 75-79.
  41. Gavras I, Gavras H . Angiotensin-converting enzyme/kininase II: hemodynamic and metabolic effects. Greek Nephrology. 2002; 14:445-448.
  42. Duka I, Shenouda S, Johns C, Kintsurashvili E, Gavras I, Gavras H. Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension. 2001 Dec 1; 38(6):1355-60. PMID: 11751717.
    View in: PubMed
  43. Gavras I, Manolis AJ, Gavras H. The alpha2 -adrenergic receptors in hypertension and heart failure: experimental and clinical studies. J Hypertens. 2001 Dec; 19(12):2115-24. PMID: 11725152.
    View in: PubMed
  44. Kintsurashvili E, Gavras I, Johns C, Gavras H. Effects of antisense oligodeoxynucleotide targeting of the alpha(2B)-adrenergic receptor messenger RNA in the central nervous system. Hypertension. 2001 Nov; 38(5):1075-80. PMID: 11711500.
    View in: PubMed
  45. Kintsurashvili E, Duka I, Gavras I, Johns C, Farmakiotis D, Gavras H. Effects of ANG II on bradykinin receptor gene expression in cardiomyocytes and vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2001 Oct; 281(4):H1778-83. PMID: 11557571.
    View in: PubMed
  46. Stefanadis C, Manolis A, Dernellis J, Tsioufis C, Tsiamis E, Gavras I, Gavras H, Toutouzas P. Acute effect of clonidine on left ventricular pressure-volume relation in hypertensive patients with diastolic heart dysfunction. J Hum Hypertens. 2001 Sep; 15(9):635-42. PMID: 11550110.
    View in: PubMed
  47. Gavras I. Is ancient Greek a dead language? Lancet. 2001 Aug 4; 358(9279):424. PMID: 11511075.
    View in: PubMed
  48. DeStefano AL, Gavras H, Heard-Costa N, Bursztyn M, Manolis A, Farrer LA, Baldwin CT, Gavras I, Schwartz F. Maternal component in the familial aggregation of hypertension. Clin Genet. 2001 Jul; 60(1):13-21. PMID: 11531965.
    View in: PubMed
  49. Gavras I, Gavras H. Role of alpha2-adrenergic receptors in hypertension. Am J Hypertens. 2001 Jun; 14(6 Pt 2):171S-177S. PMID: 11411753.
    View in: PubMed
  50. Duka I, Kintsurashvili E, Gavras I, Johns C, Bresnahan M, Gavras H. Vasoactive potential of the b(1) bradykinin receptor in normotension and hypertension. Circ Res. 2001 Feb 16; 88(3):275-81. PMID: 11179194.
    View in: PubMed
  51. Gavras I, Gavras H . The role of ACE inhibition in heart failure. In: ACE Inhibitors, editors: Pedro D'Orleans-Juste, Gerard E. Plante. Birkhauser Verlag. Basel, Switzerland. 2001; 71-79.
  52. Gavras I, Gavras H. Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT? Curr Control Trials Cardiovasc Med. 2001; 2(6):257-259. PMID: 11806808.
    View in: PubMed
  53. Gavras I, Gavras H . Role of angiotensin-converting enzyme (ACE) in the pathophysiology of hypertension. In: Angiotensin-Converting Enzyme (ACE): Clinical and Experimental Insights. Editor: Thomas D. Giles. Health Care Communications, Inc. Fort Lee,NJ. 2001; 123-126.
  54. Gavras I, Gavras H. The antiarrhythmic potential of angiotensin II antagonism: experience with losartan. Am J Hypertens. 2000 May; 13(5 Pt 1):512-7. PMID: 10826402.
    View in: PubMed
  55. Duka I, Gavras I, Johns C, Handy DE, Gavras H. Role of the postsynaptic alpha(2)-adrenergic receptor subtypes in catecholamine-induced vasoconstriction. Gen Pharmacol. 2000 Feb; 34(2):101-6. PMID: 10974417.
    View in: PubMed
  56. Nicolaou M, DeStefano AL, Gavras I, Cupples LA, Manolis AJ, Baldwin CT, Gavras H, Farrer LA. Genetic predisposition to stroke in relatives of hypertensives. Stroke. 2000 Feb; 31(2):487-92. PMID: 10657427.
    View in: PubMed
  57. Makaritsis KP, Johns C, Gavras I, Gavras H. Role of alpha(2)-adrenergic receptor subtypes in the acute hypertensive response to hypertonic saline infusion in anephric mice. Hypertension. 2000 Feb; 35(2):609-13. PMID: 10679505.
    View in: PubMed
  58. Gavras I, Gavras H . Angiotensin-converting enzyme inhibitors. In: Hypertension Medicine. Editor: Michael A. Weber. Humana Press. Totowa,NJ. 2000; 315-324.
  59. Gavras I, Gavras H . The role of AII antagonists in hypertension: Focus on telmisartan. Cardiovascular Reviews and Reports. 2000; 21:76-80.
  60. Gavras H, Gavras I . Commentary: Implications for the pathophysiology of hypertension and heart failure derived from clinical experience with drugs modifying the renin-angiotensin system. In: Drugs, Enzymes and Receptors of the Renin-Angiotensin System: Celebrating a Century of Discovery. Eds: Husain A, Graham RM. Harwood Academic Publishers. Amsterdam,The Netherlands. 2000; 187-190.
  61. Gavras H, Gavras I . Cardiac effects of angiotensin II and AT1 receptor blockade. In: Angiotensin II Receptor Antagonists. Eds.: Epstein M, Brunner HR. Hanley & Belfus, Inc. Philadelphia, PA. 2000; 215-222.
  62. Gavras I, Manolis AJ, Gavras H. The economics of therapeutic advances: the paradigm of sympathetic suppression in chronic heart failure. Arch Intern Med. 1999 Dec 13-27; 159(22):2634-6. PMID: 10597753.
    View in: PubMed
  63. Makaritsis KP, Johns C, Gavras I, Altman JD, Handy DE, Bresnahan MR, Gavras H. Sympathoinhibitory function of the alpha(2A)-adrenergic receptor subtype. Hypertension. 1999 Sep; 34(3):403-7. PMID: 10489385.
    View in: PubMed
  64. Baldwin CT, Schwartz F, Baima J, Burzstyn M, DeStefano AL, Gavras I, Handy DE, Joost O, Martel T, Manolis A, Nicolaou M, Bresnahan M, Farrer L, Gavras H. Identification of a polymorphic glutamic acid stretch in the alpha2B-adrenergic receptor and lack of linkage with essential hypertension. Am J Hypertens. 1999 Sep; 12(9 Pt 1):853-7. PMID: 10509541.
    View in: PubMed
  65. Baima J, Nicolaou M, Schwartz F, DeStefano AL, Manolis A, Gavras I, Laffer C, Elijovich F, Farrer L, Baldwin CT, Gavras H. Evidence for linkage between essential hypertension and a putative locus on human chromosome 17. Hypertension. 1999 Jul; 34(1):4-7. PMID: 10406815.
    View in: PubMed
  66. Gavras I, Gavras H. Safety and tolerability of eprosartan. Pharmacotherapy. 1999 Apr; 19(4 Pt 2):102S-107S. PMID: 10213529.
    View in: PubMed
  67. Gavras I, Manolis A, Gavras H. Genetic epidemiology of essential hypertension. J Hum Hypertens. 1999 Apr; 13(4):225-9. PMID: 10333339.
    View in: PubMed
  68. Manolis A, Dernellis J, Stefanadis C, Gavras I, Gavras H, Toutouzas P. Acute effect of clonidine on left ventricular pressue-volume relation in hypertensives with diastolic heart dysfunction. Hypertension. 1999; 34:332.
  69. Manolis AJ, Tsalopoulos E, Ramos C, Katsaros K, Dalabiras P, Hatzissavas J, Foussas S, Gavras I, M. Bresnahan, Gavras H . Benefits of central sympathetic suppression with clonidine after acute myocardial infarction. Advances in Therapy. 1999; 16:272-282.
  70. Makaritsis KP, Handy DE, Johns C, Kobilka B, Gavras I, Gavras H. Role of the alpha2B-adrenergic receptor in the development of salt-induced hypertension. Hypertension. 1999 Jan; 33(1):14-7. PMID: 9931075.
    View in: PubMed
  71. Gavras H, Gavras I . The renin-angiotensin system and the heart. In: Contemporary Endocrinology: Hormones and the Heart in Health and Disease. Ed.: Share L. Humana Press Inc. Totowa, NJ. 1999; 63-67.
  72. Gavras I, Gavras H. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin. 1999; 15(1):15-24. PMID: 10216807.
    View in: PubMed
  73. Gavras H, Gavras I . Bioactive peptides in the treatment of hypertension and heart failure. In: Bioactive Peptides in Drug Discovery and Design: Medical Aspects. Eds.: Matsoukas J, Mavromoustakos T. IOS Press. Amsterdam, Netherlands. 1999; 41-50.
  74. DeStefano AL, Baldwin CT, Burzstyn M, Gavras I, Handy DE, Joost O, Martel T, Nicolaou M, Schwartz F, Streeten DH, Farrer LA, Gavras H. Autosomal dominant orthostatic hypotensive disorder maps to chromosome 18q. Am J Hum Genet. 1998 Nov; 63(5):1425-30. PMID: 9792870.
    View in: PubMed
  75. Manolis AJ, Olympios C, Sifaki M, Smirnioudis N, Handanis S, Argirakis S, Katsaros C, Gavras I, Gavras H. Chronic sympathetic suppression in the treatment of chronic congestive heart failure. Clin Exp Hypertens. 1998 Oct; 20(7):717-31. PMID: 9764717.
    View in: PubMed
  76. Balbi AL, Franco RJ, Barretti P, Gavras I, Gavras H. Renal artery clipping attenuates the progression of adriamycin nephropathy. Am J Hypertens. 1998 Sep; 11(9):1124-8. PMID: 9752899.
    View in: PubMed
  77. Manolis AJ, Beldekos D, Handanis S, Haralabidis G, Hatzissavas J, Foussas S, Cokkinos DV, Bresnahan M, Gavras I, Gavras H. Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity. Am J Hypertens. 1998 Jun; 11(6 Pt 1):640-8. PMID: 9657622.
    View in: PubMed
  78. Gavras I, Gavras H. The calcium channel antagonist controversy. Am Fam Physician. 1998 Apr 1; 57(7):1484, 1492. PMID: 9556636.
    View in: PubMed
  79. Gavras I, Gavras H . The renin-angiotensin system in hypertensive cardiac disease. In: Renin Angiotensin. Editors: Ulfendahl HR, Aurell M. Portland Press. London,UK. 1998; 74:265-272.
  80. Gavras I, Gavras H. Salt in hypertension: physiological and molecular aspects. Recent Prog Horm Res. 1998; 53:1-6. PMID: 9769699.
    View in: PubMed
  81. Gavras H, Gavras I. Hypertension in the Elderly. Hormonal and Therapeutic Aspects. In: Recent Advances in Geriatrics, editors: Mario Barbagallo, Giuseppe Licata, James R. Sowers. Plenum Press. New York,NY. 1998; 69-74.
  82. Bakris GL, Kusmirek SL, Smith AC, Gavras I, Gavras H. Calcium antagonism abolishes the antipressor action of vasopressin (V1) receptor antagonism. Am J Hypertens. 1997 Oct; 10(10 Pt 1):1153-8. PMID: 9370387.
    View in: PubMed
  83. Manolis AJ, Beldekos D, Hatzissavas J, Foussas S, Cokkinos D, Bresnahan M, Gavras I, Gavras H. Hemodynamic and humoral correlates in essential hypertension: relationship between patterns of LVH and myocardial ischemia. Hypertension. 1997 Sep; 30(3 Pt 2):730-4. PMID: 9323014.
    View in: PubMed
  84. Bakris G, Bursztyn M, Gavras I, Bresnahan M, Gavras H. Role of vasopressin in essential hypertension: racial differences. J Hypertens. 1997 May; 15(5):545-50. PMID: 9170008.
    View in: PubMed
  85. Gavras I, Manolis A, Gavras H. Drug therapy for hypertension. Am Fam Physician. 1997 Apr; 55(5):1823-6, 1829-34. PMID: 9105208.
    View in: PubMed
  86. Gavras I, Gavras H . Potential cardioprotector de los inhibidores del enzima conversor de la angiotensina. Anales De Cirugia Cardiaca Y Cirugia Vascular. 1997; 3:185-189.
  87. Manolis AJ, Olympios C, Sifaki M, Handanis S, Cokkinos D, Bresnahan M, Gavras I, Gavras H. Combined sympathetic suppression and angiotensin-converting enzyme inhibition in congestive heart failure. Hypertension. 1997 Jan; 29(1 Pt 2):525-30. PMID: 9039154.
    View in: PubMed
  88. Kohlmann O, Cesaretti ML, Ginoza M, Tavares A, Zanella MT, Ribeiro AB, Ramos OL, Leeman SE, Gavras I, Gavras H. Role of substance P in blood pressure regulation in salt-dependent experimental hypertension. Hypertension. 1997 Jan; 29(1 Pt 2):506-9. PMID: 9039150.
    View in: PubMed
  89. Manolis AJ, Beldekos D, Hatzissavas J, Foussas S, Cokkinos D, Bresnahan M, Gavras I, Gavras H . Hemodynamic and hormonal correlates in essential hypertension. Hypertension. 1997; 29:861.
  90. Johns C, Gavras I, Handy DE, Salomao A, Gavras H. Models of experimental hypertension in mice. Hypertension. 1996 Dec; 28(6):1064-9. PMID: 8952597.
    View in: PubMed
  91. Gavras I, Gavras H. What Data Are Required to Adopt New Antihypertensive Agents? Am J Ther. 1996 Aug; 3(8):604-607. PMID: 11862298.
    View in: PubMed
  92. Gavras I, Gavras H. Cardioprotective potential of angiotensin converting enzyme inhibitors. Braz J Med Biol Res. 1996 Jun; 29(6):701-5. PMID: 9070382.
    View in: PubMed
  93. Gavras I, Gavras H. Commentary on Kostis' report from SOLVD. Am J Hypertens. 1996 Jun; 9(6):615, 616-9. PMID: 8783788.
    View in: PubMed
  94. Gavras H, Gavras I . Initiating antihypertensive therapy in the 1990s. In: ACE Inhibition & Your Practice. Ikram H, ed. English Thornton Communications, Inc. 1996; 1-6.
  95. Manolis A, Gavras I, Gavras H. Clonidine and heart failure. Hypertension (Letter to Editor). 1996; 27:1187-1188.
  96. Gavras H, Gavras I . Endothelial function in cardiovascular disease: the role of bradykinin. In: Bradykinin. Sara Black, ed. Science Press Limited. London, UK. 1996; 1-58.
  97. Kohlmann O, Ginoza M, Cezaretti ML, Zanella MT, Ribeiro AB, Tavares A, Ramos OL, Leeman SE, Gavras I, Gavras H. Cardiovascular effects of a specific nonpeptide antagonist of substance P (NK-1) receptor in DOCA-salt hypertension. Hypertension. 1995 Dec; 26(6 Pt 2):1186-9. PMID: 7498993.
    View in: PubMed
  98. Manolis AJ, Olympios C, Sifaki M, Handanis S, Bresnahan M, Gavras I, Gavras H. Suppressing sympathetic activation in congestive heart failure. A new therapeutic strategy. Hypertension. 1995 Nov; 26(5):719-24. PMID: 7591009.
    View in: PubMed
  99. Gavras H, Gavras I. Modern approaches to initiating antihypertensive therapy. Cardiol Clin. 1995 Nov; 13(4):593-8. PMID: 8565022.
    View in: PubMed
  100. Ruocco NA, Bergelson BA, Yu TK, Gavras I, Gavras H. Augmentation of coronary blood flow by ACE inhibition: role of angiotensin and bradykinin. Clin Exp Hypertens. 1995 Oct; 17(7):1059-72. PMID: 8556004.
    View in: PubMed
  101. Gavras I. Metaphors and health care reform. N Engl J Med. 1995 Jul 27; 333(4):260. PMID: 7646694.
    View in: PubMed
  102. Manolis AJ, Gavras I, Pieprzak M, Gavras H. Isradipine versus captopril in patients with essential hypertension. Clin Ther. 1995 Jul-Aug; 17(4):648-55. PMID: 8565028.
    View in: PubMed
  103. Gavras I, Manolis A, Gavras H. Effects of ACE inhibition on the heart. J Hum Hypertens. 1995 Jun; 9(6):455-8. PMID: 7473527.
    View in: PubMed
  104. Kohlman O, Neves Fde A, Ginoza M, Tavares A, Cezaretti ML, Zanella MT, Ribeiro AB, Gavras I, Gavras H. Role of bradykinin in insulin sensitivity and blood pressure regulation during hyperinsulinemia. Hypertension. 1995 May; 25(5):1003-7. PMID: 7737706.
    View in: PubMed
  105. Gavras H, Handy D, Gavras I . Alpha-adrenergic receptors in hypertension. In: Hypertension: Pathophysiology, Diagnosis, and Management, Second Edition, eds: Laragh JH, Brenner BM. Raven Press, Ltd. New York,NY. 1995; 853-861.
  106. Gavras I, Gavras H. Role of Vasopressin in Hypertensive Disorders. In:Hypertension: Pathophysiology, Diagnosis, and Management, Second Edition, eds: Laragh JH, Brenner BM. Raven Press, ltd. New York,NY. 1995; 789-800.
  107. Gavras I, Gavras H. Bradykinin in hypertension and heart disease: effects of ACE inhibition. In: ACE Report. Nicholls MG, ed. Current Science, Ltd. 1995; 1-5.
  108. Bursztyn M, Gavras I, Gourley L, DeSilva J, Whalen J, Gavras H. Effect of combination therapy with atenolol and the angiotensin-converting enzyme inhibitor benazepril. Clin Ther. 1994 May-Jun; 16(3):429-36. PMID: 7923309.
    View in: PubMed
  109. Gavras H, Gavras I. On the JNC V report. A different point of view. Am J Hypertens. 1994 Mar; 7(3):288-93. PMID: 8003283.
    View in: PubMed
  110. Franco R, Gut A, Ferrari-Spadotto A, Georgette J, Gavras I, Gavras H. Pressor mechanisms in adriamycin-induced nephropathy with hypertension in rats. Hypertension. 1994 Jan; 23(1 Suppl):I246-9. PMID: 8282368.
    View in: PubMed
  111. de Paula RB, Plavnik FL, Rodrigues CI, Neves Fde A, Kohlmann O, Ribeiro AB, Gavras I, Gavras H. Contribution of vasopressin to orthostatic blood pressure maintenance in essential hypertension. Am J Hypertens. 1993 Sep; 6(9):794-8. PMID: 8110434.
    View in: PubMed
  112. De Paula RB, Plavnik FL, Rodrigues CI, Neves Fde A, Kohlmann Júnior O, Ribeiro AB, Gavras I, Gavras H. Age and race determine vasopressin participation in upright blood pressure control in essential hypertension. Ann N Y Acad Sci. 1993 Jul 22; 689:534-6. PMID: 8373040.
    View in: PubMed
  113. Gavras I, Gavras H. ACE inhibitors: a decade of clinical experience. Hosp Pract (Off Ed). 1993 Jul 15; 28(7):117-20, 123, 126-7. PMID: 8325908.
    View in: PubMed
  114. Manolis A, Athanasopoulos G, Karatasakis G, Gavras I, Bresnahan M, Cokkinos DV, Gavras H. Pressor hormone profile during stress in hypertension: does vasopressin interfere with left ventricular hypertrophy? Clin Exp Hypertens. 1993 May; 15(3):539-55. PMID: 8490595.
    View in: PubMed
  115. Gavras I, Gavras H . Angiotensin II -- possible adverse effects on arteries, heart, brain, and kidney: Experimental, clinical, and epidemiological evidence. In: The Renin-Angiotensin System, Biochemistry Physiology, Vol, JIS Robertson, MG Nicholls, eds., pp. 40.1-40.11. Gower Medical Publishing,. London,UK. 1993.
  116. Gavras H, Gavras I . Hypertension in the elderly: Pathophysiology of aging of the cardiovascular system. In: Nephrology and Urology in the Aged Patient. Eds Oreopouloys DG, Michelis MF, Herschorn S. Kuwer Academic Publishers. 1993; 141-145.
  117. Gavras I, Gavras H . Does bradykinin contribute to the actions of angiotensin converting enzyme inhibitors?. In: Ace Report 95, MG Nicholls, ed. Current Science Ltd. 1993; 1-8.
  118. Gavras I. Bradykinin-mediated effects of ACE inhibition. Kidney Int. 1992 Oct; 42(4):1020-9. PMID: 1453578.
    View in: PubMed
  119. Wang YX, Gavras I, Wierzba T, Gavras H. Comparison of systemic and regional hemodynamic effects of a diuretic, an angiotensin II receptor antagonist, and an angiotensin-converting enzyme inhibitor in conscious renovascular hypertensive rats. J Lab Clin Med. 1992 Mar; 119(3):267-72. PMID: 1541876.
    View in: PubMed
  120. Wang YX, Gavras I, Wierzba T, Lammek B, Gavras H. Inhibition of nitric oxide, bradykinin, and prostaglandins in normal rats. Hypertension. 1992 Feb; 19(2 Suppl):II255-61. PMID: 1735588.
    View in: PubMed
  121. Gavras H, Gavras I . Hypertension in the elderly: Choosing the right therapy. J Crit Illness. 1992; 7:1862-1874.
  122. Gavras H, Gavras I . How ACE inhibition lowers blood pressure. Choices in Cardiology 6 (Suppl I). 1992; 15-17.
  123. Lammek B, Wang YX, Gavras I, Gavras H. A novel bradykinin antagonist with improved properties. J Pharm Pharmacol. 1991 Dec; 43(12):887-8. PMID: 1687595.
    View in: PubMed
  124. Gavras H, Gavras I. Angiotensin converting enzyme inhibitors. J Hypertens. 1991 Nov; 9(11):1075-6. PMID: 1661767.
    View in: PubMed
  125. Wang YX, Gavras I, Lammek B, Bresnahan M, Gavras H. Effects of bradykinin and prostaglandin inhibition on systemic and regional hemodynamics in conscious normotensive rats. J Hypertens. 1991 Sep; 9(9):805-12. PMID: 1663981.
    View in: PubMed
  126. Gavras I, Gavras H. Cardioprotective potential of angiotensin-converting enzyme inhibitors. Clin Cardiol. 1991 Aug; 14(8 Suppl 4):IV68-71; discussion IV83-90. PMID: 1893645.
    View in: PubMed
  127. Gavras H, Gavras I. Cardioprotective potential of angiotensin converting enzyme inhibitors. J Hypertens. 1991 May; 9(5):385-92. PMID: 1649858.
    View in: PubMed
  128. Wang YX, Franco R, Gavras I, Gavras H. Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and antiantidiuretic activities in rats with left ventricular dysfunction. J Lab Clin Med. 1991 Apr; 117(4):313-8. PMID: 1826304.
    View in: PubMed
  129. Lammek B, Wang YX, Franco R, Gavras I, Gavras H. Two highly effective V1/V2 antagonists of vasopressin containing novel thioacids at position 1. J Pharm Pharmacol. 1991 Jan; 43(1):40-2. PMID: 1676057.
    View in: PubMed
  130. Gavras I . Managing Hypertensive Emergencies. Contemporary Internal Med. 1991; 1:71-75.
  131. Lammek B, Wang YX, Gavras I, Gavras H. A new highly potent antagonist of bradykinin. Peptides. 1990 Nov-Dec; 11(6):1319. PMID: 2087444.
    View in: PubMed
  132. Lammek B, Wang YX, Gavras I, Gavras H. A new highly potent antagonist of bradykinin. Peptides. 1990 Sep-Oct; 11(5):1041-3. PMID: 2284196.
    View in: PubMed
  133. Bursztyn M, Bresnahan M, Gavras I, Gavras H. Effect of aging on vasopressin, catecholamines, and alpha 2-adrenergic receptors. J Am Geriatr Soc. 1990 Jun; 38(6):628-32. PMID: 2162869.
    View in: PubMed
  134. Bursztyn M, Gavras I, Tifft CP, Luther R, Boger R, Gavras H. Effects of a novel renin inhibitor in patients with essential hypertension. J Cardiovasc Pharmacol. 1990 Mar; 15(3):493-500. PMID: 1691375.
    View in: PubMed
  135. Bursztyn M, Bresnahan M, Gavras I, Gavras H. Pressor hormones in elderly hypertensive persons. Racial differences. Hypertension. 1990 Feb; 15(2 Suppl):I88-92. PMID: 2153631.
    View in: PubMed
  136. Gavras I, Gavras H . Enalapril. In: Cardiovascular Drug Therapy. ed Messerli F. WB Saunders Co. Philadelphia, PA. 1990; 792-799.
  137. Gavras I, Gavras H . Enalapril-Lisinopril. In Drugs for the Heart and Circulation, ed Messerli FH. WB Saunders Co. 1990.
  138. Gavras H, Gavras I . Effects of Bradykinin Antagonists on the Cardiovascular System. Bradykinin Antagonists Basic & Clinical Research. Ed Burch RM. Marcel Dekker. New York. 1990; 171-189.
  139. Gavras I, Gavras H. Angiotensin-converting enzyme inhibitors in hypertension and congestive heart failure. Adv Intern Med. 1990; 35:249-67. PMID: 2405595.
    View in: PubMed
  140. Wang Y-X, Lammek B, Bresnahan M, Gavras I, Gavras H. Systemic and regional hemodynamic effects of bradykinin antagonist in normal conscious rats. J Hypertens 8(Suppl 3):S3 (Abstract). 1990.
  141. Wierzba T, Manolis, Gavras I, Bursztyn M, Gavras H . Enalapril in mild to moderate hypertension. Current Therapeutic Research. 1990; 48(6):1101-1110 .
  142. Gavras I, Gavras H. The future of converting enzyme inhibitors as cardioprotective agents. Current Science. 1990; 5:626-629.
  143. Wang YX, Franco R, Gavras I, Gavras H. Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and anti-antidiuretic activities in rats with left ventricular dysfunction. Clin Res. 1990; 38:583A.
  144. Mulinari RA, Gavras I, Wang YX, Franco R, Gavras H. Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction. Circulation. 1990 Jan; 81(1):308-11. PMID: 2404626.
    View in: PubMed
  145. Bursztyn M, Gavras I, Tifft CP, Bauer JH, Melby JC, Gavras H. Renin inhibition with A-64662: effect on blood pressure and hormonal response in man. J Hypertens Suppl. 1989 Dec; 7(6):S306-7. PMID: 2698944.
    View in: PubMed
  146. Gavras H, Gavras I. Salt-induced hypertension: the interactive role of vasopressin and of the sympathetic nervous system. J Hypertens. 1989 Aug; 7(8):601-6. PMID: 2681406.
    View in: PubMed
  147. Bursztyn M, Gavras I, Gavras H. Hypertension in the aging patient. Implications for the selection of drug therapy. J Am Geriatr Soc. 1989 Aug; 37(8):814-8. PMID: 2754162.
    View in: PubMed
  148. Mulinari R, Gavras I, Franco R, Gavras H. Bradykinin antagonism and prostaglandins in blood pressure regulation. Hypertension. 1989 Jun; 13(6 Pt 2):960-3. PMID: 2567708.
    View in: PubMed
  149. Bursztyn M, Gavras I, Blasucci DJ, Gavras H. Intravenous dilevalol in the treatment of severe hypertension. J Cardiovasc Pharmacol. 1989 May; 13(5):799-802. PMID: 2472530.
    View in: PubMed
  150. Gavras I, Gavras H . Role of vasopressin in hypertensive disorders. In Hypertension: Pathophysiology, Diagnosis and Management, eds Laragh JH and Brenner BM. Raven Press. New York,NY. 1989; 779-789.
  151. Bursztyn M, Gavras I, Gavras H . Quinapril: Mechanism of action, safety, and effectiveness. Inter Med. 1989; 10:79-85.
  152. Mulinari R, Gavras I, Gavras H. The role of vasopressin in blood pressure regulation. In Perspectives in Hypertension: II Endocrine mechanisms of Hypertension, eds Brenner BM, Kaplan N, and Laragh JH. Raven Press. New York,NY. 1989; 201-218.
  153. Gavras I, Mulinari R, Gavras H. Renin-angiotensin and vasopressin in the development of salt-induced hypertension. J Hypertens. 1988 Dec; 6(12):999-1002. PMID: 2975694.
    View in: PubMed
  154. Gavras I, Gavras H. Anti-hormones and blood pressure: bradykinin antagonists in blood pressure regulation. Kidney Int Suppl. 1988 Oct; 26:S60-2. PMID: 3059034.
    View in: PubMed
  155. Mulinari RA, Gouni I, Gavras I, Gavras H. Acute effects of the new angiotensin-converting enzyme inhibitor cilazapril: a pilot study. J Clin Pharmacol. 1988 Jul; 28(7):660-3. PMID: 2975290.
    View in: PubMed
  156. Mulinari R, Benetos A, Gavras I, Gavras H. Vascular and sympathoadrenal responses to bradykinin and a bradykinin analogue. Hypertension. 1988 Jun; 11(6 Pt 2):754-7. PMID: 2899059.
    View in: PubMed
  157. Gavras I, Gavras H. Role of bradykinin in hypertension and the antihypertensive effect of angiotensin-converting enzyme inhibitors. Am J Med Sci. 1988 Apr; 295(4):305-7. PMID: 2834950.
    View in: PubMed
  158. Gavras H, Gavras I. Angiotensin converting enzyme inhibitors. Properties and side effects. Hypertension. 1988 Mar; 11(3 Pt 2):II37-41. PMID: 3280490.
    View in: PubMed
  159. Saad CI, Ribeiro AB, Zanella MT, Mulinari RA, Gavras I, Gavras H. The role of vasopressin in blood pressure maintenance in diabetic orthostatic hypotension. Hypertension. 1988 Feb; 11(2 Pt 2):I217-21. PMID: 3346060.
    View in: PubMed
  160. Gavras I, Mulinari R, Ribeiro A, Gavras H . Role of vasopressin in hypertension and heart failure: Clinical Studies. In Vasopressin : Cellular and Integrative Functions, ed Cowley AW. Raven Press. New York,NY. 1988; 467-479.
  161. Gavras I, Bursztyn M, Gavras H . Changing trends in hypertension therapy: ACE inhibitors and calcium blockers. Mod Medicine. 1988; 56:106-117.
  162. Gavras I, Mulinari R, Gavras H, Higgins JT, Reeves RL, Zawada ET, Crook J, Halperin AK, Garrett B. Antihypertensive effectiveness of the nifedipine gastrointestinal therapeutic system. Am J Med. 1987 Dec 21; 83(6B):20-3. PMID: 3332575.
    View in: PubMed
  163. Svetkey LP, Weinberger MH, Gavras H, Gavras I, Brown TS, Deterding J, Klotman PE. Double-blind, placebo-controlled trial of twice-daily nifedipine as a step-2 agent in mild essential hypertension. J Clin Hypertens. 1987 Dec; 3(4):579-88. PMID: 3330988.
    View in: PubMed
  164. Benetos A, Bresnahan M, Gavras I, Gavras H. Central catecholamines and alpha-adrenoceptors in acute hypertension induced by intracerebroventricular hypertonic saline. J Hypertens. 1987 Dec; 5(6):699-704. PMID: 2828469.
    View in: PubMed
  165. Gavras H, Benetos A, Gavras I. Contribution of bradykinin to maintenance of normal blood pressure. Hypertension. 1987 Jun; 9(6 Pt 2):III147-9. PMID: 3596781.
    View in: PubMed
  166. Benetos A, Gavras I, Gavras H. Stimulation of vasopressin by calcium microinjections in the area of the paraventricular nucleus of the hypothalamus. Brain Res. 1987 May 26; 412(1):182-4. PMID: 3607454.
    View in: PubMed
  167. Gavras I, Gavras H. [Clinical management of hypertension in the elderly]. Rev Clin Esp. 1987 Mar; 180(5):229-31. PMID: 3602521.
    View in: PubMed
  168. Gavras I, Gavras H . The role of angiotensin converting enzyme inhibitors in hypertension. In: The pharmacological treatment of cardiovascular diseases. Editors, Kostis JB, DeFelice EA, MEPC. Alan Liss Inc. New York,NY. 1987; 93-122.
  169. Papadoliopoulou-Diamandopoulou N, Papagalanis N, Gavras I, Gavras H. Vasopressin in end-stage renal disease: relationship to salt, catecholamines and renin activity. Clin Exp Hypertens A. 1987; 9(7):1197-208. PMID: 3304733.
    View in: PubMed
  170. Benetos A, Gavras H, Stewart JM, Vavrek R, Hatinoglou S, Gavras I. The antihypertensive contribution of bradykinin as assessed by a specific bradykinin antagonist. Agents Actions Suppl. 1987; 22:355-64. PMID: 2829598.
    View in: PubMed
  171. Gavras I, Gavras H . Clinical management of hypertension in the elderly. In: Hypertension in the Community, Eds Rosenthal T, Silderberg D. Karger Publ. 1987; 62-67.
  172. Mulinari R, Gavras I, Gavras H. Efficacy and tolerability of enalapril monotherapy in mild-to-moderate hypertension in older patients compared to younger patients. Clin Ther. 1987; 9(6):678-89. PMID: 2830974.
    View in: PubMed
  173. Gavras I, Gavras H. Clinical management of hypertension in the elderly. Bibl Cardiol. 1987; (42):62-7. PMID: 3632619.
    View in: PubMed
  174. Bresnahan MR, Gavras I, Hatinoglou S, Muller RE, Gavras H. Central alpha-adrenoceptors during the development of hypertension in rats on high and low salt intake. J Hypertens. 1986 Dec; 4(6):719-26. PMID: 3029217.
    View in: PubMed
  175. Benetos A, Gavras I, Gavras H. Hypertensive effect of a bradykinin antagonist in normotensive rats. Hypertension. 1986 Nov; 8(11):1089-92. PMID: 3770870.
    View in: PubMed
  176. Benetos A, Gavras H, Stewart JM, Vavrek RJ, Hatinoglou S, Gavras I. Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension. 1986 Nov; 8(11):971-4. PMID: 3021624.
    View in: PubMed
  177. Gavras I, Gavras H. Clinical utility of angiotensin converting enzyme inhibitors in hypertension. Am J Med. 1986 Oct 31; 81(4C):28-31. PMID: 3022582.
    View in: PubMed
  178. Benetos A, Gavras I, Gavras H. Norepinephrine applied in the paraventricular hypothalamic nucleus stimulates vasopressin release. Brain Res. 1986 Sep 3; 381(2):322-6. PMID: 3827993.
    View in: PubMed
  179. Gavras I, Hatinoglou S, Benetos A, Gavras H. Calcium stimulates vasopressin release. J Hypertens. 1986 Aug; 4(4):451-4. PMID: 3772099.
    View in: PubMed
  180. Gavras I, Hatinoglou S, Gavras H. The adrenergic system and the release and pressor action of vasopressin. Hypertension. 1986 Jun; 8(6 Pt 2):II163-7. PMID: 2873100.
    View in: PubMed
  181. Strauss R, Gavras I, Vlahakos D, Gavras H. Enalaprilat in hypertensive emergencies. J Clin Pharmacol. 1986 Jan; 26(1):39-43. PMID: 3005376.
    View in: PubMed
  182. Ribeiro A, Mulinari R, Gavras I, Kohlmann O, Ramos O, Gavras H . Sequential elimination of pressor mechanisms in severe hypertension in humans. Hypertension 8(Suppl I):I-169-I-173. 1986.
  183. Gavras H, Gavras I . Inhibitors of the renin-angiotensin system. In: Tratado Sobre Hipertension Arterial. JL Rodicio, ed. Madrid. 1986.
  184. Vlahakos D, Gavras I, Gavras H. alpha-Adrenoceptor agonists applied in the area of the nucleus tractus solitarii in the rat: effect of anesthesia on cardiovascular responses. Brain Res. 1985 Nov 18; 347(2):372-5. PMID: 2866015.
    View in: PubMed
  185. Gavras H, Bain GT, Bland L, Vlahakos D, Gavras I. Hypertensive response to saline microinjection in the area of the nucleus tractus solitarii of the rat. Brain Res. 1985 Sep 16; 343(1):113-9. PMID: 2994826.
    View in: PubMed
  186. Gavras I, Gavras H. Nifedipine in the treatment of essential hypertension. J Clin Pharmacol. 1985 Sep; 25(6):429-32. PMID: 3902911.
    View in: PubMed
  187. Kohlmann O, Gavras I, Biollaz J, Biollaz B, Gavras H. Sodium chloride-induced partial inhibition in vivo of alpha 2-adrenoceptor agonist function. J Hypertens. 1985 Jun; 3(3):269-74. PMID: 2862207.
    View in: PubMed
  188. Gavras H, Gavras I . Managing hypertensives with parenchymal renal disease. Cardiovasc Med. 1985; 10(2):43-54.
  189. Gavras H, Gavras I. Interaction of vasopressin with the sympathetic nervous system and arterial pressure and control. In: Vasopressin, Robert W Schrier, ed. Raven Press. New York,NY. 1985; 39-44.
  190. Gavras H, Gavras I . Risk of stroke in the hypertensive elderly patient. Geriatric Med Today. 1985; 4(11):72-75.
  191. Gavras I, Vlahakos D, Melby JC, Gavras H. Pilot study of the effects of the angiotensin-converting enzyme inhibitor CI-906 on patients with essential hypertension. J Clin Pharmacol. 1984 Aug-Sep; 24(8-9):343-50. PMID: 6090509.
    View in: PubMed
  192. Biollaz B, Biollaz J, Kohlman O, Bresnahan M, Gavras I, Gavras H. Acute cardiovascular effects of two central phenylethanolamine-N-methyl-transferase inhibitors in unanesthetized desoxycorticosterone-salt hypertensive rats. Eur J Pharmacol. 1984 Jul 20; 102(3-4):515-9. PMID: 6489438.
    View in: PubMed
  193. Hatzinikolaou P, Gavras H, North WG, Kohlmann O, Gavras I. Evidence for dopaminergic regulation of vasopressin release in the anephric rat. J Hypertens. 1984 Jun; 2(3):311-5. PMID: 6442313.
    View in: PubMed
  194. Gavras H, Ribeiro AB, Kohlmann O, Saragoça M, Mulinari RA, Ramos O, Gavras I. Effects of a specific inhibitor of the vascular action of vasopressin in humans. Hypertension. 1984 Mar-Apr; 6(2 Pt 2):I156-60. PMID: 6547112.
    View in: PubMed
  195. Charocopos F, Hatzinikolaou P, Gavras I, Gavras H. Regional blood flows and cardiac hemodynamics in renovascular and mineralocorticoid hypertensive rats. J Physiol (Paris). 1984; 79(3):162-5. PMID: 6381695.
    View in: PubMed
  196. DiPette D, Gavras I, North W, DiPette P, Gavras H. Vasopressin response to hyperosmotic stimulus: blood pressure effect in normal subjects and patients with impaired sympathetic system. Clin Exp Hypertens A. 1984; 6(4):851-61. PMID: 6723091.
    View in: PubMed
  197. Waeber B, Gavras H, Bresnahan MR, Gavras I, Brunner HR. Role of vasoconstrictor systems in experimental glucocorticoid-hypertension in rats. Clin Sci (Lond). 1983 Sep; 65(3):255-61. PMID: 6872460.
    View in: PubMed
  198. Gavras I, Gavras H. Captopril and enalapril. Ann Intern Med. 1983 Apr; 98(4):556-7. PMID: 6301322.
    View in: PubMed
  199. DiPette D, Waeber B, Volicer L, Chao P, Gavras I, Gavras H, Brunner H. Salt-induced hypertension in chronic renal failure: evidence for a neurogenic mechanism. Life Sci. 1983 Feb 14; 32(7):733-40. PMID: 6827908.
    View in: PubMed
  200. Hatzinikolaou P, Charocopos F, Gavras I, Gavras H. Systemic and regional hemodynamic effects of propranolol in intact and anephric rats. Clin Exp Hypertens A. 1983; 5(5):729-39. PMID: 6883742.
    View in: PubMed
  201. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I. Clinical application of orally active angiotensin converting enzyme inhibitors. In Kinins-III, Part B, H Fritz, N Back, G Dietze, GL Haberland, eds. Plenum Press. New York. 1983; 1127-1131.
  202. Gavras H, Gavras I. Hypertension in the elderly. John Wright PS Inc. Boston,MA. 1983.
  203. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I. Clinical application of orally active angiotensin converting enzyme inhibitors. Adv Exp Med Biol. 1983; 156 (Pt B):1127-31. PMID: 6305164.
    View in: PubMed
  204. Gavras I, Gavras H . Captoril and Enalapril. Ann Int Med (Reply to Letter). 1983; 99:281.
  205. Waeber B, Gavras H, Gavras I, Chao P, Kohlman O, Bresnahan MR, Brunner HR, Vaughan D. Evidence for a sodium-induced activation of central neurogenic mechanisms in one-kidney, one-clip renal hypertensive rats. J Pharmacol Exp Ther. 1982 Nov; 223(2):510-5. PMID: 6752375.
    View in: PubMed
  206. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982 Nov-Dec; 4(6):966-72. PMID: 6185790.
    View in: PubMed
  207. DiPette DJ, Gavras I, North WG, Brunner HR, Gavras H. Vasopressin in salt-induced hypertension of experimental renal insufficiency. Hypertension. 1982 May-Jun; 4(3 Pt 2):125-30. PMID: 7068202.
    View in: PubMed
  208. Gavras H, Hatzinikolaou P, North WG, Bresnahan M, Gavras I. Interaction of the sympathetic nervous system with vasopressin and renin in the maintenance of blood pressure. Hypertension. 1982 May-Jun; 4(3):400-5. PMID: 7040232.
    View in: PubMed
  209. Waeber B, Gavras I, Brunner HR, Cook CA, Charocopos F, Gavras HP. Prediction of sustained antihypertensive efficacy of chronic captopril therapy: relationships to immediate blood pressure response and control plasma renin activity. Am Heart J. 1982 Mar; 103(3):384-90. PMID: 6278905.
    View in: PubMed
  210. Gavras I, Gavras H. Leukopenia: idiopathic or drug-induced? N Engl J Med. 1982 Feb 25; 306(8):484. PMID: 7057850.
    View in: PubMed
  211. Dipette D, Dipette P, North W, Gavras I, Brunner HR, Gavras H . Plasma vasopressin response to hyperosmotic solution (renograffin) and its effect on blood pressure in quadriplegic patients. Clin Res. 1982; 30:510.
  212. Gavras I, Gavras H, Chobanian AV, Tifft CP, Melby JC, Jick H. Hypertension and age: clinical and biochemical correlates. Clin Exp Hypertens A. 1982; 4(7):1097-106. PMID: 6749343.
    View in: PubMed
  213. Hatzinikolaou P, Gavras I, North W, Brunner HR, Gavras H. Interaction of the sympathetic nervous system with vasopressin and renin in the maintenance of blood pressure in rats. Clin Sci. 1982; 63:313s-317s.
  214. Gavras I . Work-up of the hypertensive patient. In Clinical Hypertension and Hypotension. Brunner HR, Gavras I, eds. Marcel Dekker Inc. New York,NY. 1982.
  215. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I. Clinical application of orally active angiotensin converting enzyme inhibitors. In Mechanisms of action of antihypertensive drugs. CT Dollery, ED Frohlich eds. Guadalajara. Mexico. 1982.
  216. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I, Davies RO. Effects of the new oral angiotensin converting enzyme inhibitor MK-421 in human hypertension. Clin Exp Hypertens A. 1982; 4(1-2):303-14. PMID: 6280900.
    View in: PubMed
  217. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I, Sackel H, Charocopos F, Davies RO. Effects of the oral angiotensin-converting enzyme inhibitor MK-421 in human hypertension. Clin Sci (Lond). 1981 Dec; 61 Suppl 7:281s-283s. PMID: 6274572.
    View in: PubMed
  218. Waeber B, Gavras I, Brunner HR, Gavras H. Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update. J Clin Pharmacol. 1981 Nov-Dec; 21(11-12 Pt 1):508-16. PMID: 6460791.
    View in: PubMed
  219. Gavras H, Brunner HR, Gavras I. Captopril in the treatment of hypertension. Ann Intern Med. 1981 Oct; 95(4):505-6. PMID: 7025722.
    View in: PubMed
  220. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I, Davies RO. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421". Lancet. 1981 Sep 12; 2(8246):543-7. PMID: 6116000.
    View in: PubMed
  221. Black J, Waeber B, Bresnahan MR, Gavras I, Gavras H. Blood pressure response to central and/or peripheral inhibition of phenylethanolamine N-methyltransferase in normotensive and hypertensive rats. Circ Res. 1981 Aug; 49(2):518-24. PMID: 7249286.
    View in: PubMed
  222. Gavras H, Waeber B, Kershaw GR, Liang CS, Textor SC, Brunner HR, Tifft CP, Gavras I. Role of reactive hyperreninemia in blood pressure changes induced by sodium depletion in patients with refractory hypertension. Hypertension. 1981 Jul-Aug; 3(4):441-7. PMID: 7030951.
    View in: PubMed
  223. Hatzinikolaou P, Gavras H, Brunner HR, Gavras I. Role of vasopressin, catecholamines, and plasma volume in hypertonic saline-induced hypertension. Am J Physiol. 1981 Jun; 240(6):H827-31. PMID: 7246746.
    View in: PubMed
  224. Gavras H, Charocopos F, Brunner H, Gavras I. Angiotensin converting enzyme inhibition: a new therapeutic modality. Bull N Y Acad Med. 1981 May; 57(4):304-10. PMID: 6164426.
    View in: PubMed
  225. Gavras I, Gavras H, Tifft CP, Kershaw GR, Bresnahan M. Effect of pindolol on blood pressure, plasma renin activity, and catecholamines in hypertensive patients. J Clin Pharmacol. 1981 Feb-Mar; 21(2):79-83. PMID: 7014658.
    View in: PubMed
  226. Gavras H, Gavras I, Brunner HR . Hypertension, vasopressors and the susceptibility to vascular injury: experimental and clinical studies. In Frontiers in Hypertension Research, Laragh JH, Buhler F, Seldin DW, eds. Springer-Verlag. New York,NY. 1981; 412-413.
  227. Gavras I, Graff LG, Rose BD, McKenna JM, Brunner HR, Gavras H. Fatal pancytopenia associated with the use of captopril. Ann Intern Med. 1981 Jan; 94(1):58-9. PMID: 7004300.
    View in: PubMed
  228. Gavras H, Gavras I, Brunner HR. Clinical relevance of reactive hyperreninemia. Res and Staff Phys. 1981; 27:67-72.
  229. Gavras H, Hatzinikolaou P, Brunner HR, Gavras I . Clinical applications of angiotensin blockade. Eighth International Congress of Nephrology, Athens. W Zurukzoglou, M Papadimitriou, M Pyrpasopoulos, M Sion, C Zamboulis, eds. Basel: S Karger. 1981; 1060-1066.
  230. Gavras H, Gavras I, Brunner HR. Vasoconstriction and sodium volume factors in renovascular hypertension. Frontiers in Hypertension Research, JH Laragh, F Buhler, DW Seldin, eds. 1981; 159-164.
  231. Gavras H, Gavras I . The renin angiotensin system in hypertension. In: Contemporary Issues in Nephrology, Hypertension, Brenner BM, Stein JH, eds. Churchill, Livingston. New York,NY. 1981; 8:65-99.
  232. Hatzinikolaou P, Gavras H, Brunner HR, Gavras I. Sodium-induced elevation of blood pressure in the anephric state. Science. 1980 Aug 22; 209(4459):935-6. PMID: 7403861.
    View in: PubMed
  233. Gavras I, Gavras H. Special considerations in treating hypertension in the elderly. Geriatrics. 1980 Jul; 35(7):34-40. PMID: 7380255.
    View in: PubMed
  234. Gavras H, Gavras I, Brunner HR. Angiotensin inhibitors for hypertension. Compr Ther. 1980 May; 6(5):14-8. PMID: 6155240.
    View in: PubMed
  235. Gavras H, Gavras I, Textor S, Tifft CP, Kershaw GR, Brunner HR. The use of SQ 20881 converting enzyme inhibitor (teprotide) for diagnostic purposes in hypertension. In: Captopril and Hypertension. D Case, E Sonnenblick, JH Laragh, eds. Plenum Medical Book Company. New York,NY. 1980; 210-214.
  236. Gavras H, Gavras I, Hadzinikolaou P, Brunner HR . Inhibition of angiotensin conversion: its role in treatment of hypertension and congestive heart failure. J Cardiovasc Med. 1980; 5:327-335.
  237. Gavras H, Gavras I, Brunner HR, Liang CS. Physiologic studies with saralasin in animals. Kidney Int Suppl. 1979 Mar; (9):S20-8. PMID: 384069.
    View in: PubMed
  238. Volicer L, Liang CS, Gavras H, Tifft CP, Kershaw GR, Gavras I, Griffith DL, Vukovitch R, Brunner HR. Effect of nadolol in treatment of hypertension. J Clin Pharmacol. 1979 Feb-Mar; 19(2-3):137-47. PMID: 33998.
    View in: PubMed
  239. Gavras I, Gavras H, Sullivan PC, Tifft CP, Chobanian AV, Brunner HR. A comparative study of the effects of oxprenolol versus propranolol in essential hypertension. J Clin Pharmacol. 1979 Jan; 19(1):8-14. PMID: 368088.
    View in: PubMed
  240. Brunner HR, Gavras H, Waeber B, Kershaw GR, Turini GA, Vukovich RA, McKinstry DN, Gavras I. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med. 1979 Jan; 90(1):19-23. PMID: 217289.
    View in: PubMed
  241. Brunner HR, Gavras H, Waeber B, Turini GA, McKinstry DN, Vukovich RA, Gavras I. Orally active angiotensin-converting enzyme inhibitor (SO 14,225) as a treatment for essential hypertension. Br J Clin Pharmacol. 1979; 7 Suppl 2:205S-211S. PMID: 223614.
    View in: PubMed
  242. Gavras H, Gavras I, Brunner HR. Converting enzyme inhibition in the diagnosis and treatment of hypertension. In: Controversies in Nephrology. chreiner, JF Winchester, W Mattern, BF Mendelson,. 1979; 260-268.
  243. Tifft CP, Gavras H, Kershaw GR, Gavras I, Brunner HR, Liang CS, Chobanian AV. Converting enzyme inhibition in hypertensive emergencies. Ann Intern Med. 1979 Jan; 90(1):43-7. PMID: 420460.
    View in: PubMed
  244. Gavras I, Gavras H, Brunner HR, Liang CS. Antihypertensive action of beta-adrenoceptor blockade and the renin-angiotensin system. Br J Clin Pharmacol. 1979; 7 Suppl 2:213S-217S. PMID: 37876.
    View in: PubMed
  245. Waeber B, Gavras H, Brunner HR, Chappuis P, Turini GA. [Chronic treatment of hypertension by an inhibitor of angiotensin converting enzyme]. Schweiz Med Wochenschr. 1978 Dec 9; 108(49):1981-3. PMID: 219469.
    View in: PubMed
  246. Chobanian AV, Gavras H, Melby JC, Gavras I, Jick H. Relationship of basal plasma noradrenaline to blood pressure, age, sex, plasma renin activity and plasma volume in essential hypertension. Clin Sci Mol Med Suppl. 1978 Dec; 4:93s-96s. PMID: 282107.
    View in: PubMed
  247. Chobanian AV, Garvras H, Gavras I, Bresnahan M, Sullivan P, Melby JC. Studies on the activity of the sympathetic nervous system in essential hypertension. J Human Stress. 1978 Sep; 4(3):22-8. PMID: 690418.
    View in: PubMed
  248. Gavras H, Brunner HR, Turini GA, Kershaw GR, Tifft CP, Cuttelod S, Gavras I, Vukovich RA, McKinstry DN. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med. 1978 May 4; 298(18):991-5. PMID: 205788.
    View in: PubMed
  249. Gavras H, Gavras I, Textor S, Volicer L, Brunner HR, Rucinska EJ. Effect of angiotensin converting enzyme inhibition on blood pressure, plasma renin activity and plasma aldosterone in essential hypertension. J Clin Endocrinol Metab. 1978 Feb; 46(2):220-6. PMID: 220274.
    View in: PubMed
  250. Gavras H, Gavras I . Angiotensin inhibition: a new approach to the treatment of hypertension. Iatriki. 1978; 34:521-525.
  251. Chobanian AV, Gavras H, Melby JC, Gavras I, Jick H. Relationship of basal plasma norepinephrine to blood pressure, plasma renin activity, mineralocorticoids, and plasma volume in essential hypertension. Trans Assoc Am Physicians. 1978; 91:368-80. PMID: 754399.
    View in: PubMed
  252. Gavras H, Gavras I, Cannon PJ, Brunner HR, Laragh JH. Is elevated plasma renin activity of prognostic importance in progressive systemic sclerosis? Arch Intern Med. 1977 Nov; 137(11):1554-8. PMID: 921442.
    View in: PubMed
  253. Gavras H, Flessas A, Ryan TJ, Brunner HR, Faxon DP, Gavras I. Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension. JAMA. 1977 Aug 22; 238(8):880-2. PMID: 577978.
    View in: PubMed
  254. Gavras H, Gavras I, Brunner HR, Laragh JH. The antihypertensive action of methyldopa in relation to its effect on the renin-aldosterone system. J Clin Pharmacol. 1977 Jul; 17(7):372-8. PMID: 881470.
    View in: PubMed
  255. Gavras H, Gavras I, Brunner HR, Laragh JH. Effect of a new beta-adrenergic blocker, l-bunolol, on blood pressure and on the renin-aldosterone system. J Clin Pharmacol. 1977 May-Jun; 17(5-6):350-7. PMID: 323300.
    View in: PubMed
  256. Gavras H, Ribeiro AB, Gavras I, Brunner HR. Reciprocal relation between renin dependency and sodium dependency in essential hypertension. N Engl J Med. 1976 Dec 2; 295(23):1278-83. PMID: 980059.
    View in: PubMed
  257. Gavras H, Ribeiro A, Brunner HR, Gavras I. Determination of renin-dependency and sodium-dependency in the three renin sub-groups of essential hypertension. Clin Sci Mol Med Suppl. 1976 Dec; 3:197s-200s. PMID: 1071607.
    View in: PubMed
  258. Tietjen GW, Chien S, LeRoy EC, Gavras I, Gump FE. Proceedings: Changes in blood viscosity and plasma proteins with Raynaud's phenomenon. J Cardiovasc Surg (Torino). 1976 Jan-Feb; 17(1):86. PMID: 1245517.
    View in: PubMed
  259. Brunner HR, Gavras H, Ribeiro AB, Posternak L. Angiotensin II blockade in normal man and patients with essential hypertension. Blood pressure effects depending on renin and sodium balance. Prog Biochem Pharmacol. 1976; 12:145-62. PMID: 1019161.
    View in: PubMed
  260. Brunner HR, Gavras H. Pathophysiological concepts of renovascular hypertension. Contrib Nephrol. 1976; 3:20-9. PMID: 1026366.
    View in: PubMed
  261. Tietjen GW, Chien S, Leroy EC, Gavras I, Gavras H, Gump FE. Blood viscosity, plasma proteins, and Raynaud syndrome. Arch Surg. 1975 Nov; 110(11):1343-6. PMID: 53042.
    View in: PubMed
  262. Gavras H, Brunner HR, Laragh JH, Gavras I, Vukovich RA. The use of angiotensin-converting enzyme inhibitor in the diagnosis and treatment of hypertension. Clin Sci Mol Med Suppl. 1975 Jun; 2:57s-60s. PMID: 1077792.
    View in: PubMed
  263. Gavras H, Brunner HR, Laragh JH, Vaughan ED, Koss M, Cote LJ, Gavras I. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res. 1975 Feb; 36(2):300-9. PMID: 234807.
    View in: PubMed
  264. Gavras H, Brunner HR, Laragh JH, Sealey JE, Gavras I, Vukovich RA. An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med. 1974 Oct 17; 291(16):817-21. PMID: 4371298.
    View in: PubMed
  265. Gavras H, Brunner HR, Gavras I, Laragh JH. Letter: Hypotensive effect of angiotensin-converting-enzyme inhibitor SQ 20,881. Lancet. 1974 Aug 10; 2(7876):353. PMID: 4136088.
    View in: PubMed
  266. Vaughan ED Jr, Laragh JH, Gavras I, Buhler FR, Gavras H, Brunner HR, Baer L . The volume factor in low and normal renin essential hypertension. Its treatment with either spironolactone or chlorothalidone. In: Hypertension Manual, Laragh JH, ed. Dunn-Donnelly Publ Co. New York,NY. 1974; 851-871.
  267. Vaughan ED, Laragh JH, Gavras I, Bühler FR, Gavras H, Brunner HR, Baer L. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. Am J Cardiol. 1973 Sep 20; 32(4):523-32. PMID: 4729722.
    View in: PubMed
  268. Vaughn ED Jr, Buhler FR, Gavras I, Brunner HR, Baer L, Laragh JH . Spirolactone compared to diuretic therapy in analysis and treatment of normal and low renin hypertension. Circulation 45-46(Suppl II):83. 1972.
  269. Gavras I, Thomson JA. Late thyrotoxicosis complicating autoimmune thyroiditis. Acta Endocrinol (Copenh). 1972 Jan; 69(1):41-6. PMID: 4111375.
    View in: PubMed
  270. Velenzas HG, Matsoukis-Gavras I, Ikkos DG . Idiopathic hypoparathyroidism. Iatriki Epitheoresis Enoplon Dynameon. 1971; 5:561-572.
  271. Ikkos DG, Fraser GR, Matsouki-Gavra E, Petrochilos M. Association of juvenile diabetes mellitus, primary optic atrophy and perceptive hearing loss in three sibs, with additional idiopathic diabetes mellitus insipidus in one case. Acta Endocrinol (Copenh). 1970 Sep; 65(1):95-102. PMID: 5468975.
    View in: PubMed
  272. Ikkos D, Gavras I, Dermertzis H . Male infertility caused by congenital aplasia of the vas deferens. Iatriki. 1968; 13:382.
  273. Samios B, Matsoukis-Gavras I . Sheehan's syndrome as a cause of sudden death. Iatrika Chronika. 1967; 7:38.
  274. Samios B, Ioannidis B, Matsoukis-Gavras I. The liver of diabetic patients. Bulletin of the Medical Society of Athens, February. 1966.
  275. Matsoukis-Gavras I. Biological and histological study of the liver in diabetic patients. Doctoral Dissertation, Athens. 1965.
  276. Samios B, Matsoukis-Gavras I . A case of bronchial adenoma. Nosokomiaka Chronika. 1965; 27:549.
  277. Ioannides B, Matsoukis-Gavras I. Statistical analysis of diabetics admitted to the Second Medical Clinic of Athens University School of Medicine in the years 1958-1963. Bulletin of the Tenth Panhellenic Medical Congress of the Medical Surgical Society of Athens. 1964.
  278. Franco RJS, Wang Y-Z, Mulinari R, Bresnahan M, Gavras I, Gavras H:. Vasopressor role of endogenous bradykinin in renovascular hypertensive rats chronically treated with converting enzyme inhibitor ramipril. XIth International Congress of Nephrology Abstract, Tokyo, Japan. 7/15-20-90..
Irene's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department